Beyond the patent cliff: a country-level scenario analysis of the global GLP-1 affordability gap and the limits of procurement-based access
Background GLP-1 receptor agonists are highly effective obesity treatments, and approaching patent expiries should lower prices substantially. Whether even deep price reductions would make treatment affordable at country level is unclear. We present a country-level scenario analysis of how many adults with obesity live in countries—and, within countries, income strata—where a modeled annual treatment cost exceeds an affordability threshold defined against national economic capacity. Methods We combined World Bank data on obesity prevalence, adult population, and GDP per capita (USD and PPP) for 192 countries. For six price scenarios—branded ($6,829), generic ($300), pooled procurement ($210/$150/$90), and production-cost lower bound ($28)—we computed an affordability ratio (annual cost ÷ GDP per capita) and classified countries or income quintiles as exceeding the threshold where this ratio exceeded 1% (primary), 5%, or 10%. Because national averages mask within-country inequality, we also compared mean income with country-specific median and quintile incomes (114 countries, 879 million adults with obesity) and imputed quintile shares for the remainder. We also modeled diabetes and tiered pricing. Results We estimated 977 million adults with obesity in 192 countries. At the 1% threshold, the branded price left 879 of 879 million main-sample adults in countries above the threshold (977 million imputed). At $300 this fell to 695 million (USD) and 585 million (PPP); at $90, to 465 million (USD) and 182 million (PPP); and at $28, to 204 million (USD) and 25 million (PPP). Accounting for within-country inequality widened rather than narrowed the gap at deep discounts. Results were robust to the threshold (390 million at 5% and 243 million at 10%, at $300), out-of-pocket share, and obesity-by-income assumptions. Restricting to adults with diabetes still left 666 million in countries above the threshold at $300. Income-tiered pricing with Canadian high-income prices did not reduce the residual gap, and low-income countries remained almost fully excluded at every price. Conclusion Price reductions alone did not close the affordability gap. The residual gap was concentrated in low- and lower-middle-income countries and the poorest quintiles. Closing it requires lower prices, financing, tiered pricing, and delivery investment targeting the countries and strata identified here.
Authors
- Ruirui Lin
Institutions
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3389/fpubh.2026.1974795
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00